STC BIOLOGICS, INC
LC015, a multi-targeting ligand trap therapeutic that binds ERBB family ligands to block receptor signaling in cancer cells
- Sector
- Biotech
- Total capital
- $3.1M
- Federal grants
- $300K
- 1 award · 2015
- Rank in peer group#8 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $2.8M
- 3 awards · Health and Human S
- Rank in Biotech#113 of 4373
- Granted patents
- 1
- 5 pending · first 2018
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Federal contractHealth and Human S · Igf::ot::igf Stc Biologics, INC.:1183217 [15-011968]$6K
- Federal grantHealth and Human S · Phase I · A Multi-Targeting Ligand Trap to Overcome resistance in BRAF Mutant Colorectal Cancer$300K
- Federal contractHealth and Human S · Igf::ot::igf SBIR Phase II Topic 275, "development Of Generic Trastuzumab For The Treatment Of Breast Cancer."$2.5M
- Federal contractHealth and Human S · TAS::75 0849::TAS The Goal Of This Project Is To Develop Stc Trastuzumab, A Generic Version Of Herceptin. Trastuzumab Is A Monoclonal Antibody Made Against The HER2 Protein That Is Overexpressed In 20-25% Of Patients With Breast Cancer. Because Of Very High Cost Associated With Prescribing Herceptin, A Generic Version Of This Drug Would Make Cancer Treatment More Affordable To A Wider Segment Of The Population And Lower The Cost Burden On Government-sponsored Healthcare Programs.$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#8 · top 2%
- Granted patents#70 · top 18%
- Linked publications#17 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 6- PendingBispecific Targeting Agents And Methods For Their PreparationUSPTOApplication 16069119
- PendingA Method For Development Of Recombinant Proteins With Fingerprint Like Similarity To The Reference ProductUSPTOApplication 15322857
- GrantedMethod for Optimizing Post-Translational Modifications on Recombinant ProteinsUSPTOUS 9,868,973
Show all 6 patent records
- Bispecific Targeting Agents And Methods For Their PreparationJan 3, 2019 · Application 16069119Pending
- A Method For Development Of Recombinant Proteins With Fingerprint Like Similarity To The Reference ProductJun 28, 2018 · Application 15322857Pending
- Method for Optimizing Post-Translational Modifications on Recombinant ProteinsJan 16, 2018 · US 9,868,973Granted
- Bispecific Targeting Agents And Methods For Their PreparationApplication PCTUS2017013006Pending
- A Method For Development Of Recombinant Proteins With Fingerprint Like Similarity To The Reference ProductApplication PCTUS2015038888Pending
- Method For Determination Of Pharmacological Properties Of Recombinant ProteinsApplication PCTUS2012063279Pending
Recent research by its founders
- Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier20261 cites
- Pre-clinical development of an enzyme replacement therapy (CPI-601) for CLN1 Batten disease: process development, stability and uptake studies in different species20250 cites
- Pre-clinical development of an enzyme replacement therapy for CLN1 Batten disease: Process development, stability and uptake studies20250 cites
Related companies, and why
- AKINA, INC.Similar federal contract value in Biotech · $3M in contracts
- ACTIVE MOTIF, INC.Similar federal contract value in Biotech · $2.9M in contracts
- ARUNA BIO, INC.Similar federal contract value in Biotech · $2.9M in contracts
- SYNVITROBIO, INC.Similar federal contract value in Biotech · $2.8M in contracts
- EPIBONE, INC.Similar federal contract value in Biotech · $2.8M in contracts
- AGILE SCIENCES, INC.Similar federal contract value in Biotech · $2.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .